An Update on Alopecia and its Association With Thyroid Autoimmune Diseases
Touch ENDOCRINOLOGY,
Alopecia is comorbid with several illnesses, including various autoimmune conditions such as thyroid disease.
Alopecia is comorbid with several illnesses, including various autoimmune conditions such as thyroid disease.
The skin is the body’s largest organ, and dermatologists must be able to treat a variety of pathologies, including infectious…
临床疗效与患者结局建立的联系十分紧密,SALT评分工具的重现性高,主观干扰因素较低。已经进入研发后期阶段的JAKs抑制剂,临床疗效较为明确,并且针对12岁及以上青少年和成人斑秃患者(包括全秃和普秃)的安全性和耐受性良好; 六日评新药 剖析当下热门品种,聚焦早…
MADRID.- El mundo feliz de una niña de 11 años comenzó a desmoronarse un día del verano de 2015.
El mundo feliz de una niña de 11 años comenzó a desmoronarse un día del verano de 2015.
Slideshow A 15-year-old girl presents with patches of hair loss on her scalp that have been present for the last 6 months.
NEW YORK--(BUSINESS WIRE) August 04, 2021-- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3…
We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.
Aug. 4, 2021 10:45 UTC ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth NEW YORK--(BUSINESS…
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
– ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – NEW YORK–(BUSINESS WIRE)–Pfizer Inc.
- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
(NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib…
In this article: – ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – NEW YORK, August 04…
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily…
– (NYSE:) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib…
– ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – Pfizer Inc.
– ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – NEW YORK--(BUSINESS WIRE)--Pfizer Inc.
If you’ve noticed patchy or thinning spots on your scalp or a surplus of hair strands on your hairbrush or in the shower, you're…
If you’ve noticed patchy or thinning spots on your scalp or a surplus of hair strands on your hairbrush or in the shower, you're…
From Good Housekeeping If you’ve noticed patchy or thinning spots on your scalp or a surplus of hair strands on your hairbrush…
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral…
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral…
Sept. 5, 2018 12:50 UTC Phase II data accepted for late-breaker news session at 2018 EADV Congress NEW YORK--(BUSINESS WIRE)-…
Phase II data accepted for late-breaker news session at 2018 EADV Congress Pfizer Inc.
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-066…
NEW YORK --(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-0…
NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-0…
Summary Bayer's lymphoma entry gets fast tracked. Concert Pharma gets halted in its hair loss trial.